Navigation Links
Hard to Treat Diseases (HTDS) Collagenna Skin Care Business Model and Chilean Update
Date:3/4/2010

ons, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. New Alzheimers Prevention Efforts, and Non-Drug Treatments, Featured at 25th Conference of Alzheimers Disease International
2. Montecatini Eating Disorders Program Announces 'Log In & Learn' Webinar Series for Treatment Professionals
3. Targeting leukemia cells gene addiction presents new strategy for treatment
4. BioCosmetic Center Utilizes FDA Approved Fractional Laser Treatment for Stretch Marks
5. Europes top football venues are not prepared for treating spectators who suffer heart attacks
6. PINC trial launched to test new treatment for pre-invasive breast cancer
7. Hard to Treat Diseases (HTDS) Releases 09 Financials
8. UMass Lowell researchers findings suggest new ways to diagnose and treat Alzheimers
9. Aderans Research Treats One-Hundredth Subject in Clinical Study
10. New Treatment Eyed for Deadly Pancreatic Cancer
11. Connecticut Governor Jodi Rell Honors Mountainside Addiction Treatment Center for its Twelve Years of Operating in Connecticut
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2014)... of Manchester have discovered why medication to treat asthma and ... Nature Medicine , show that drugs widely used to treat ... In the UK pneumonia, which is caused by an infection, ... more serious for babies, young children, the elderly, smokers and ... 5 million people in the UK are affected by asthma ...
(Date:7/27/2014)... Over the past five years, the ... thanks to many consumers valuing the taste and versatility ... Association of Canada's Canadian Coffee Drinking Study in 2011 ... per day. “This trend, coupled with many studies that ... tea on a daily basis, has stimulated consumer demand ...
(Date:7/27/2014)... The report, “Oil Filter & Fuel ... HCVs), Market Type (OE & Aftermarket), Filter Type (Oil ... - Industry Trends & Forecast to 2018”, defines and ... with analysis and forecasting of the global volume and ... to reach a revenue of $6.1 billion in 2018, ...
(Date:7/27/2014)... 1-Butene is a colorless, combustible gas with a ... be manufactured either through the separation from crude C4 ... alpha olefin (alkene) 1-Butene is a versatile chemical that ... chemicals such as linear light density polyethylene (LLDP), polybutene-1, ... market is extremely competitive. The market has several market ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 Metachromatic ... a lysosomal storage disease which is commonly listed ... among the sphingolipidoses as it affects the metabolism ... of myelin, the fatty covering which acts as ... and peripheral nervous systems. MLD involves cerebroside sulfate ...
Breaking Medicine News(10 mins):Health News:Drugs used to treat lung disease work with the body clock 2Health News:Coffee and Tea Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Coffee and Tea Production in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 2Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 3Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 4Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 5Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 2Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 3Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 4Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 2Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 3Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 4Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 5
... , MONDAY, Aug. 1 (HealthDay News) -- ... mental health disorders are at increased risk for chronic ... study. Researchers examined data from people in 10 ... Health Surveys initiative. The team looked at anxiety disorders ...
... mothers experienced psychological trauma during their pregnancies show signs ... The researchers discovered that this prenatal exposure to stress ... aging processes. The study results, which appear online this ... of Sciences , point to the importance of maternal ...
... (August 1, 2011) Two new studies published in ... Medicine (JNM) provide insight into the potential of ... dementia and to identify pharmaceuticals to slow the progress ... and the Alzheimer,s Association guidelines for detecting Alzheimer,s-related brain ...
... (HealthDay News) -- Despite the popularity of colon cleansing, ... done at home or in day spas -- offers any ... can cause serious side effects ranging from vomiting to kidney ... Colon cleansing -- also called colonic irrigation or colonic hydrotherapy ...
... leukemia chemotherapy drug may help breast cancer patients ... the widely-used drug, new research from the ... Interestingly, researchers found that taxoxifen combined with dasatinib, ... by cancer-associated fibroblasts in the surrounding tissue by ...
... July 31 (HealthDay News) -- A gene variant associated ... a team of researchers working together in a new ... gene variant was not present in European Americans and ... be identified in black Americans. The researchers, analysis ...
Cached Medicine News:Health News:Childhood Depression, Anxiety Tied to Pain in Adulthood 2Health News:UCI-led study links prenatal exposure to stress with accelerated cell aging 2Health News:New JNM research supports upcoming Alzheimer's disease guidelines 2Health News:Colon Cleansing Has No Health Benefit, May Harm: Report 2Health News:Leukemia drug reverses tamoxifen-resistance in breast cancer cells 2
(Date:7/25/2014)... , July 25, 2014 ... Market Research "Global and China Insulin Market (Rapid-Acting, Short-Acting, ... Analysis, Size, Share, Growth, Trends and Forecast (Value and ... valued at USD 19.99 billion in 2012 and is ... 2013 to 2019 to reach USD 32.24 billion in ...
(Date:7/25/2014)... Laboratories, Inc. (NASDAQ: IDXX ) today reported ... 11% versus the prior year period to $390 million. ... of 2014 versus the prior year period was 9%, ... . Earnings per diluted share ("EPS") for the quarter ... year period to $1.10."In the second quarter, we continued ...
(Date:7/25/2014)... Leading events organizer UBM Live announces that CPhI ... São Paulo, Brazil from 5 th ... co-locate with Food Ingredients South America (FiSA), creating ... pharmaceutical industry.      (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) Three ... exploring the South America market as ...
Breaking Medicine Technology:Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4IDEXX Laboratories Announces Second Quarter Results 2IDEXX Laboratories Announces Second Quarter Results 3IDEXX Laboratories Announces Second Quarter Results 4IDEXX Laboratories Announces Second Quarter Results 5IDEXX Laboratories Announces Second Quarter Results 6IDEXX Laboratories Announces Second Quarter Results 7IDEXX Laboratories Announces Second Quarter Results 8IDEXX Laboratories Announces Second Quarter Results 9IDEXX Laboratories Announces Second Quarter Results 10IDEXX Laboratories Announces Second Quarter Results 11IDEXX Laboratories Announces Second Quarter Results 12IDEXX Laboratories Announces Second Quarter Results 13IDEXX Laboratories Announces Second Quarter Results 14IDEXX Laboratories Announces Second Quarter Results 15IDEXX Laboratories Announces Second Quarter Results 16IDEXX Laboratories Announces Second Quarter Results 17IDEXX Laboratories Announces Second Quarter Results 18IDEXX Laboratories Announces Second Quarter Results 19IDEXX Laboratories Announces Second Quarter Results 20IDEXX Laboratories Announces Second Quarter Results 21IDEXX Laboratories Announces Second Quarter Results 22IDEXX Laboratories Announces Second Quarter Results 23IDEXX Laboratories Announces Second Quarter Results 24IDEXX Laboratories Announces Second Quarter Results 25IDEXX Laboratories Announces Second Quarter Results 26IDEXX Laboratories Announces Second Quarter Results 27IDEXX Laboratories Announces Second Quarter Results 28IDEXX Laboratories Announces Second Quarter Results 29IDEXX Laboratories Announces Second Quarter Results 30IDEXX Laboratories Announces Second Quarter Results 31IDEXX Laboratories Announces Second Quarter Results 32IDEXX Laboratories Announces Second Quarter Results 33
... 2011 /PRNewswire-Asia/ -- Shenzhen Wuzhou Changlian International ... company in China, unveiled its currently  ongoing ... today, as the company and the partners ... signing of future cooperation. Shenzhen ...
... NEW YORK, Feb. 1, 2011 Reportlinker.com announces that ... catalogue: Dry Powder Inhalation ... The convergence of socioeconomic and technology factors – the ... expected acceleration in protein- and peptide-based therapeutics, the availability ...
Cached Medicine Technology:Ongoing Negotiation on Top Brand Health Device Cooperation 2Reportlinker Adds Dry Powder Inhalation 2
... Pro Osteon Bone Graft Substitutes a natural ... from cadaver bone, but such grafts may ... disease transmission. Interpore Cross has developed the ... to address these needs, offering surgeons a ...
... osteoconductive matrix constructed of cross-linked collagen ... hydroxyapatite through a proprietary 360 accretion ... marrow aspirate, Healos provides an excellent ... and differentiation. The hydroxyapatite-coated collagen microfibers ...
Weitlaner-Locktite retractors, blunt, 11 cm total length....
Sharp Weitlaner Retractor....
Medicine Products: